Posts Tagged pharma

Keeping pace

PME Pharmaceutical Market Europe June 2017

It was a bumper issue of PME this month as we encompassed creativity, communications and consumerism, and tackled different strands of how pharma looks to reach and engage with its stakeholders.

On an industry level the German pharma market looks set for stable, if not strong, growth over the next four years, but it’s clearly anyone’s guess what will happen over that timeframe to the UK’s political landscape, and how that will in turn affect the industry.

What we can say with certainty is that European regulators aren’t waiting for the region’s politicians to thrash out a deal on the post-Brexit landscape. Instead the last month has seen concrete developments in the future shape of the regulatory environment, with a set of guidance now available, and – more recently – a delay to deciding the new location of the EMA. Read the rest of this entry »

, , ,

Leave a comment

Up in the air

PME Pharmaceutical Market Europe May 2017

Stranger things have been said by politicians, particularly recently, but I can’t have been the only person surprised by Greg Clark’s turn at this year’s ABPI annual conference.

Asked about the EMA Clark, the UK government’s spokesperson for business, energy and industrial strategy, told the UK pharma gathering he wanted “as many [European] institutions here as possible”, adding: “I would like the EMA to continue to be within the UK.”

Meanwhile, in the real world, the temperature is certainly rising on the issue of where Europe’s regulatory authority will be located, with ‘not in the UK’ seemingly the only certainty at the moment. A decision from the EU’s heads of government is expected in the Autumn, and Copenhagen, Barcelona, Dublin and Lisbon are among those stepping up their public campaigns to host the EMA. Read the rest of this entry »

, , , , , ,

Leave a comment

A marathon, not a sprint

PME Pharmaceutical Market Europe April 2017

The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.

Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.

Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »

, , , , ,

Leave a comment

Employee engagement and nurturing talent in pharma

PME Pharmaceutical Market Europe March 2017

You won’t generally find PME issues following a particular theme each month – there’s simply too much interesting ground to cover in the magazine for that.

Nevertheless, as each issue coalesces there are often common strands across different features and such seemed the case with March’s PME, which contains a nice chunk of ‘careers’ content.  Read the rest of this entry »

, , , , , , , , ,

Leave a comment

Ready to start?

PME Pharmaceutical Market Europe January 2017

As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.

This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »

, , , ,

Leave a comment

The changing world

pme_pharmaceutical_market_europe_november_2016_lrg

For this month’s issue of PME I spoke with Ipsen’s new chief executive David Meek about his company’s strategy for growth and – appropriately enough, as we sat down at the ESMO meeting in Copenhagen – his hopes for Ipsen’s new cancer drug Cabometyx.

We covered the strategic pillars Ipsen is counting on for success and looked at the strong progress the French firm is making in the US – where for the first year its operations there are its number one affiliate by revenue – and the changes to its primary care business model in China. Read the rest of this entry »

, , , , , , ,

Leave a comment

Be bold

PME Pharmaceutical Market Europe October 2016There’s no shortage of ambition at GlaxoSmithKline, whose chief immunology officer and senior vice president of their R&D pipeline Paul-Peter Tak we spoke to for this month’s executive interview.

Having joined the company five years ago from an academic medical centre in Amsterdam, he says he was driven to move to the industry because he wanted to have a bigger impact on patients’ lives. Read the rest of this entry »

, , , , ,

Leave a comment

%d bloggers like this: